Diabetes mellitus and chronic liver diseases. Part 1: general mechanisms of etiology and pathogenesis


Cite item

Full Text

Abstract

In recent years there has been an active discussion about the relationship between diabetes mellitus (DM) and chronic liver diseases (CLD). On the one hand, patients with diabetes have an increased risk of developing CLD. On the other hand, patients with CLD very often identify abnormal glucose metabolism which ultimately leads to impaired glucose tolerance and the development of diabetes. This review outlines potential causal relationships between some CLD and DM. Common mechanisms that provoke metabolic and autoimmune disorders in the development of various nosologies of the CKD group, leading to steatosis, insulin resistance, impaired glucose tolerance and the development of diabetes are described. Certain features of the assessment of carbohydrate metabolism compensation in patients with hepatic dysfunction, anemia and protein metabolism disorders are described.

About the authors

Z A Kalmykova

Endocrinology Research Centre

Email: zilya.kalmykova@gmail.com
клинический ординатор; ORCID: 0000-0002-2612-5253 Moscow, Russia

I V Kononenko

Endocrinology Research Centre

к.м.н., в.н.с. отд. прогнозирования и инноваций диабета Института диабета, доц. каф. диабетологии и диетологии Института высшего и дополнительного профессионального образования ФГБУ «НМИЦ эндокринологии» Moscow, Russia

A Yu Mayorov

Endocrinology Research Centre

д.м.н., зав. отд. прогнозирования и инноваций диабета Института диабета, проф. каф. диабетологии и диетологии Института высшего и дополнительного профессионального образования ФГБУ «НМИЦ эндокринологии»; ORCID: 0000-0001-5825-3287 Moscow, Russia

References

  1. IDF Diabetes atlas. 7th ed. 2015. Available from: http://www.diabetesatlas.org. Accessed July 29, 2018.
  2. Stasi C, Silvestri C, Voller F, Cipriani F. Epidemiology of Liver Cirrhosis. J Clin Exp Hepatol. 2015;5(3):272. doi: 10.1016/j.jceh.2015.06.002
  3. García-Compeán D, González-González J.A, Lavalle-González F.J, et al. Hepatogenous diabetes: Is it a neglected condition in chronic liver disease? World J Gastroenterol. 2016;22(10):2869-74. doi: 10.3748/wjg.v22.i10.289
  4. Conn H.O, Schreiber W, Elkington S.G. Cirrhosis and diabetes II. Association of impaired glucose tolerance with portal - systemic shunting in Laennec’s cirrhosis. Am J Dig Dis. 1971;16(3):227-39.
  5. Tolman K.G, Fonseca V, Dalpiaz A, Tan M.H. Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease. Diabetes Care. 2007;30(3):734-43. doi: 10.2337/dc06-1539
  6. Khan R, Foster R, Chowdhury A. Managing Diabetes in Patients with Chronic Liver Disease. Postgrad Med. 2012;124(4):130-7. doi: 10.3810/pgm.2012.07.2574
  7. Ткачук В.А, Воротников А.В. Молекулярные механизмы развития резистентности к инсулину. Сахарный диабет. 2014;17(2):29-40. doi: 10.14341/DM2014229-40
  8. Saini V. Molecular mechanisms of insulin resistance in type 2 diabetes mellitus. World J Diabetes. 2010;1(3):68. doi: 10.4239/wjd.v1.i3.68
  9. Мишина Е.Е, Майоров А.Ю, Богомолов П.О и др. Неалкогольная жировая болезнь печени: причина или следствие инсулинорезистентности? Сахарный диабет. 2017;20(5):335-43. doi: 10.14341/DM9372
  10. Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2018 Sep. doi: 10.1016/j.mam.2018.09.002
  11. Kiziltas S. Toll - like receptors in pathophysiology of liver diseases. World J Hepatol. 2016;8(32):1354-69. doi: 10.4254/wjh.v8.i32.1354
  12. García-Compeán D, Jáquez-Quintana J.O, Lavalle-González F.J, et al. The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study. Ann Hepatol. 2012;11(2):240-8. doi: 10.1016/S1665-2681(19)31030-0
  13. Martínez-Esparza M. Inflammatory status in human hepatic cirrhosis. World J Gastroenterol. 2015;21(41):11522. doi: 10.3748/wjg.v21.i41.11522
  14. Coffin C.S, Fraser H.F, Panaccione R, Ghosh S. Liver diseases associated with anti - tumor necrosis factor - alpha (TNF-α) use for inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(1):479-84. doi: 10.1002/ibd.21336
  15. Yang Y.M, Seki E. TNFα in Liver Fibrosis. Curr Pathobiol Rep. 2015;3(4):253-61. doi: 10.1007/s40139-015-0093-z
  16. Borst S.E. The Role of TNF-α in Insulin Resistance. Endocrine. 2004;23(2-3):177-82. doi: 10.1385/ENDO:23:2-3:177
  17. Sawada M, Kiyono T, Nakashima S, et al. Molecular mechanisms of TNF-α - induced ceramide formation in human glioma cells:P53-mediated oxidant stress - dependent and independent pathways. Cell Death Differ. 2004;11(9):997-1008. doi: 10.1038/sj.cdd.4401438
  18. Meex R.C.R, Watt M.J. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat Rev Endocrinol. 2017;13(9):509-20. doi: 10.1038/nrendo.2017.56
  19. Hammerstad S.S, Grock S.F, Lee H.J, Hasham A. Diabetes and hepatitis C: a two - way association. Front Endocrinol. 2015;6(September). doi: 10.3389/fendo.2015.00134
  20. Kingston M.E, Ali M.A, Atiyeh M, Donnelly R.J. Diabetes mellitus in chronic active hepatitis and cirrhosis. Gastroenterology. 1984;87(3):688-94.
  21. Huang J.F, Dai C.Y, Hwang S.J, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007;102(6):1237-43. doi: 10.1111/j.1572-0241.2007.01181.x
  22. Hong Y.S, Chang Y, Ryu S, et al. Hepatitis B and C virus infection and diabetes mellitus: A cohort study. Sci Rep. 2017;7(1):4606. doi: 10.1038/s41598-017-04206-6
  23. Analytic and Reporting Guidelines: The Third National Health and Nutrition Examination Survey, NHANES III (1988-94). doi: 10.3886/ICPSR02231.v1
  24. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased Risk of Type 2 Diabetes in Noncirrhotic Patients With Chronic Hepatitis C Virus Infection. Mayo Clin Proc. 2000;75(4):355-9. doi: 10.4065/75.4.355
  25. Pattullo V, Heathcote J. Hepatitis C and diabetes: one treatment for two diseases? Liver Int. 2009;30(3):356-64. doi: 10.1111/j.1478-3231.2009.02185.x
  26. Bose S.K. Hepatitis C virus infection and insulin resistance. World J Diabetes. 2014;5(1):52. doi: 10.4239/wjd.v5.i1.52
  27. Akyürek N, Atabek M.E, Eklioglu B.S. Possible Associations of Acut Hepatitis B With New - onset Type 1 Diabetes: A Case Report. Gazi Med J. 2015;26(2). doi: 10.12996/gmj.2015.21
  28. Chen L.K, Chou Y.C, Tsai S.T, Hwang S.J, Lee S.D. Hepatitis C virus infection - related Type 1 diabetes mellitus. Diabet Med. 2005;22(3):340-3. doi: 10.1111/j.1464-5491.2005.01412.x
  29. Targher G, Marchesini G, Byrne C.D. Risk of type 2 diabetes in patients with non - alcoholic fatty liver disease: Causal association or epiphenomenon? Diabetes Metab. 2006;42(3):142-56. doi: 10.1016/j.diabet.2016.04.002
  30. Shah R.V, Allison M.A, Lima J.A.C, et al. Liver fat, statin use, and incident diabetes: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2015;242(1):211-7. doi: 10.1016/j.atherosclerosis.2015.07.018
  31. Kumashiro N, Erion D.M, Zhang D, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci. 2011;108(39):16381-5. doi: 10.1073/pnas.1113359108
  32. Allen K.J, Gurrin L.C, Constantine C.C, et al. Iron-Overload - Related Disease in HFE Hereditary Hemochromatosis. N Engl J Med. 2008;358(3):221-30. doi: 10.1056/NEJMoa073286
  33. Еремина Е.Ю. Гемохроматоз в практике клинициста. Медицинский альманах. 2015;36(1):74-8.
  34. Mitchell T.C, Mcclain D.A. Diabetes and Hemochromatosis. Curr Diabet Rep. 2014;14:488. doi: 10.1007/s11892-014-0488-y
  35. Moczulski D.K, Grzeszczak W, Gawlik B. Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. Diabetes Care. 2001;24(7):1187-91.
  36. Ellervik C, Mandrup-Poulsen T, Nordestgaard B.G, et al. Prevalence of hereditary haemochromatosis in late - onset type 1 diabetes mellitus: a retrospective study. Lancet. 2001;358:1405-9. doi: 10.1016/S0140-6736(01)06526-6
  37. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. и др. Клинические рекомендации Российского общества по изучению печени по ведению взрослых пациентов с алкогольной болезнью печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(6):20-40. doi: 10.22416/1382-4376-2017-27-6-20-40
  38. Baliunas O, Taylor J, Irving H, et al. Alcohol as a Risk Factor for Type 2 Diabetes. Diabetes Care. 2009;32(11):2123-32. doi: 10.2337/dc09-0227
  39. Koko V, Todorović V, Nikolić J.A, et al. Rat pancreatic B-cells after chronic alcohol feeding. A morphometric and fine structural study. Histol Histopathol. 1995;10(2):325-7.
  40. Wei M, Gibbons L.W, Mitchell T.L, Kampert J.B B.S. Alcohol intake and incidence of type 2 diabetes in men. Diabetes Care. 2000;23(1):18-22.
  41. Nilsson A, Tideholm B, Kalén J.K.P. Incidence of severe hypoglycemia and its causes in insulin - treated. Acta Med Scand. 1988;224(3):257-62.
  42. Ribeiro R, Marinho R.T, Suri J.S, Sanches J.M. Classification and Staging of Chronic Liver Disease Based on Ultrasound, Laboratorial, and Clinical Data. In: Ultrasound Imaging. Boston, MA: Springer US; 2012. P. 255-82. doi: 10.1007/978-1-4614-1180-2_11
  43. Angulo P, Kleiner D.E, Dam-Larsen S, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long - term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389-97.e10. doi: 10.1053/j.gastro.2015.04.043
  44. Kim M.G, Choi W.C. [Differential diagnosis of diabetes mellitus caused by liver cirrhosis and other type 2 diabetes mellitus]. Korean J Hepatol. 2006;12(4):524-9.
  45. Acevedo J.G, Cramp M.E. Hepatorenal syndrome: Update on diagnosis and therapy. World J Hepatol. 2017;9(6):293-9. doi: 10.4254/wjh.v9.i6.293
  46. Gangopadhyay K.K. Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. Ind J Endocrinol Metab. 2017;21(2):341-54. doi: 10.4103/ijem.IJEM
  47. Моргунов Л.Ю. Сахарный диабет у пациентов с циррозом печени:новые возможности лечения. Исследования и практика в медицине. 2017;4(3):75-85. doi: 10.17709/2409-2231-2017-4-3-7

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies